天境生物科技（上海）有限公司 IMab
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer 2021-01-26 05:05
I-Mab Announces Upcoming Participation at January Conferences 2020-12-23 21:00
I-Mab Added to Nasdaq Biotechnology Index 2020-12-14 21:00
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China 2020-12-04 21:00
I-Mab Files Shelf Registration Statement for PIPE Investors 2020-12-02 05:23
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board 2020-12-01 21:00
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 2020-11-11 21:00
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting 2020-11-09 21:12
I-Mab Announces Upcoming Participation at November Conferences 2020-10-28 20:00
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020-10-27 20:05
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency 2020-09-30 20:00
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma 2020-09-21 20:00
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer 2020-09-18 04:05
I-Mab Announces Upcoming Participation at September Conferences 2020-09-08 20:00
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium 2020-09-04 19:01
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy 2020-09-04 19:00
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update 2020-08-31 19:00
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China 2020-08-17 20:00
I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020 2020-08-06 20:30
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency 2020-08-04 20:17
1 4 5 6 7 8